In a post-hoc analysis of these two large, pivotal, multinational trials, opicapone was effective regardless of baseline presence of dyskinesia and of concurrent rasagiline use [3,4]. In another post-hoc analysis, opicapone was effective in reducing motor fluctuations in âearly fluctuatorsâ, resulting in a significant proportion of responders (achieving at least 1 hour of OFF-time reduction or 1 hour of ON-time increase), similar to the total study population [5].
In the 1-year extension of the BIPARK-I study, the placebo and entacapone groups switched to open-label opicapone. During this period there was no worsening of non-motor symptoms for subjects in these groups [6]. Patients who had switched from placebo presented significantly less disability. At the end of the double-blind period, total scores on the Non-Motor Symptoms Scale (NMSS) in the 199 âswitchersâ had decreased in all treatment groups. Mean changes from baseline were -5.7, -4.7, and -2.0 for placebo, entacapone, and opicapone 50 mg, respectively. During the 1-year extension the scores further decreased: -3.8 (P=0.041), -0.2 (P=0.899), and -0.4 (P=0.849), respectively.
- Ferreira J, et al. Lancet Neurology 2016;15(2):154-65.
- Lees A, et al. JAMA Neurol. 2017;74(2):197-206.
- Fabregues O, et al. EAN 2019, EPO1198.
- Lees A, et al. EAN 2019, EPO2174.
- Ferreira J, et al. EAN 2019, EPR1075.
- Lees A, et al. EAN 2019, EPO2176.
Posted on
Previous Article
« Randomised and observational studies comparing treatments Next Article
Clinical and cost effectiveness of levetiracetam vs valproate »
« Randomised and observational studies comparing treatments Next Article
Clinical and cost effectiveness of levetiracetam vs valproate »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimerâs Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimerâs
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
November 11, 2021
CTA identifies stroke patients most likely to benefit from thrombectomy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com